Editor’s note: A recording of the conversation is embedded below.
Every week, STAT+ subscribers get access to exclusive content with biotech, pharma, and health tech leaders. This week, STAT’s senior writer of medicine and editorial director of events Matthew Herper will be joined by STAT’s national biotech reporter, Damian Garde. They will be discussing the FDA’s landmark decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, and of course be taking your questions live.
Create a display name to comment
This name will appear with your comment